Discovery Life Sciences will acquire the Gentest business from Corning Incorporated.

BIOLOGICAL LEADER COMBINES GENTEST WITH RECENT IVAL ACQUISITION TO CREATE THE BEST IN VITRO DRUG METABOLISM SERVICE OFFER

HUNTSVILLE, Alabama, April 6, 2022 /PRNewswire/ – Discovery of the life sciences™ (Discovery), specialist in biosamples and biomarkers ™, today announced the acquisition of the Gentest® division, part of the company’s Life Sciences division Corning Inc.. The acquisition of Gentest complements Discovery’s recent acquisition of In Vitro ADMET Laboratories, LLC (IVAL) last December and makes Discovery a leading provider of in vitro drug testing systems for industry, pharmaceuticals and the life sciences.

The Gentest portfolio includes capture and transport reagents, recombinant metabolic enzymes, tissue fractions, hepatocytes, other ADME toxicology products, and contract research services. Their portfolio complements Discovery’s existing ADME and toxicology solutions, which include cryopreserved hepatocytes and enterocytes, and related services developed and managed by Albert Lee, world-renowned hepatocyte expert and Discovery’s scientific director of pharmacology and toxicology.

The combination of these companies enhances Discovery’s ability to provide scientific expertise in the development of drugs and biomarkers based on bioassays. This reinforces the company’s leading position in the biologics market, as Discovery can now offer researchers access to one of the world’s largest microsome and hepatocyte reserves, as well as cutting-edge technologies and extensive scientific services. The result is a unique innovation engine that helps deliver actionable results that enable clients to manage their drug development programs more efficiently and cost-effectively.

“We are thrilled to welcome the brilliant scientific experts and outstanding talents behind Corning’s Gentest portfolio to the Discovery team,” said Mr. Li of in vitro experimental approaches to evaluating drug metabolism, drug interactions, toxicology and pharmacology along with our combination unrivaled technology enables Discovery to provide the most advanced in vitro research products and services of the highest quality to research communities and drug development laboratories. »

About Discovery Life Sciences and HudsonAlpha Discovery

Discovery Life Sciences is a biosamples and biomarkers company that combines the world’s largest commercial biosamples stock and supply chain with preeminent biomarker service labs to accelerate the development of new biomarker-supported therapies and the accompanying diagnosis of cancer, infectious diseases, and more. rare and complex diseases. terms. We are a leading provider of high quality human cell raw materials and expert multi-ohm analytical services to advance research, development and manufacturing programs in cell and gene therapy.

HudsonAlpha Discovery® is the sequencing and bioinformatics division of Discovery, a globally recognized service laboratory that uses state-of-the-art genomics research technologies to comprehensively support discovery, translational and clinical research.

With leading scientific expertise and innovative use of modern technology, the Discovery team engages and consults with customers to overcome obstacles faster and deliver insights for critical R&D decisions at market speed. We are science at your service™! (Science at your service!) For more information, visit dls.com.

Leave a Comment